Skip to main content
OpenTrials
Completed

NCT Number: NCT04560647

Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions

The purpose of this study is to understand the role of a specific protein, tumor protein p63 in the skin disease psoriasis. This study is to further understand how psoriasis lesions happens. An understanding of key mediators that lead to psoriasis might aid in the discovery of more effective treatments for this skin disorder. This is not an intervention study. The study is looking to obtain currently untreated plaque psoriasis biopsies and also biopsies from non psoriasis patients. Psoriasis and medical history will be collected then skin biopsies will be obtained from the subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Wright State Physicians

Fairborn, Ohio, 45324, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female and Male adult subjects age 18 to 50 with plaque psoriasis that is currently untreated (no topical agents for 2 weeks, no systemic agents for 1 month) or controls w/o psoriasis and no family history of psoriasis.
  • Must be able to give informed consent
  • All skin types on Fitzpatrick Scale (Type I-VI)
  • Able to provide medical history and list of medications for psoriasis and control subjects

Exclusion criteria

  • Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)
  • Tanning bed use within last 2 months
  • Photodynamic Therapy or UVB treatments in past 2 months
  • Female Subjects: pregnant or nursing
  • History of abnormal scarring (i.e., keloids)
  • Family history of psoriasis in first-degree relatives for control subjects

Treatment and study plan

No intervention - Psoriasis Subject

Other

Not currently treated plaque psoriasis patients

No intervention - Control Subject

Other

Control subjects without plaque psoriasis and no family history of psoriasis

Primary outcomes

  1. Abnormal P63 signaling levels

    Time frame: Day 0

    Determining if untreated psoriasis skin has abnormal p63 signaling

Sponsors and collaborators

Lead sponsor

Wright State University

Other

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Sep 23, 2020
Registry last updated
Apr 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.